Low molecular weight compounds with transition metals as free radical scavengers and novel therapeutic agents

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2010, Pages 128-146

  Bencini, Andrea ^a   Failli, Paola ^a   Valtancoli, Barbara ^a   Bani, Daniele ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Free radical scavenger(s); Nitric oxide; Reactive oxygen species; Superoxide anion; Transition metals

Indexed keywords

COBALT COMPLEX; COPPER; CYANOCOBALAMIN; DIETHYLENTRIAMINEPENTAACETIC ACID; DITHIOCARBAMIC ACID; EDETIC ACID; EDETIC ACID RUTHENIUM; EGTAZIC ACID; EGTAZIC ACID RUTHENIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETHYLENE BISGLYCOL TETRACETIC ACID; FERRIOXAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; IRON COMPLEX; MANGANESE; MANGANESE SUPEROXIDE DISMUTASE; N (2 HYDROYETHYL)ETHYLENEDIAMINE N,N',N' TRIACETIC ACID RUTHENIUM; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; PENTETIC ACID; PENTETIC ACID RUTHENIUM; REACTIVE OXYGEN METABOLITE; RUTHENIUM; RUTHENIUM COMPLEX; SCAVENGER; SUPEROXIDE DISMUTASE; TRANSITION ELEMENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER INHIBITION; CARDIAC GRAFT REJECTION; CATABOLISM; CHEMICAL BOND; CLINICAL TRIAL; CRYSTAL STRUCTURE; CYANIDE POISONING; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOTENSION; INORGANIC CHEMISTRY; MIGRAINE; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; SEPTIC SHOCK; SHOCK; TISSUE INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FREE RADICAL SCAVENGERS; MOLECULAR WEIGHT; NITRIC OXIDE; ORGANOMETALLIC COMPOUNDS; REACTIVE OXYGEN SPECIES; TRANSITION ELEMENTS;

EID: 77954706008     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510791698389     Document Type: Article

References (142)

1. Gerschman, R.; Gilbert, D.L.; Nye, S.W.; Dwyer, P.; Fenn, W.O.Oxygen poisoning and x-irradiation: a mechanism in common.Science, 1954, 119(3097), 623-626.
2. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. Nitric oxide physiology,pathophysiology, and pharmacology. Pharmacol. Rev., 1991,43(2), 109-142.
3. McCord, J.M.; Fridovich, I. Superoxide dismutase: an enzymaticfunction for erythrocuprein (hemocuprein). J. Biol. Chem., 1969,244(22), 6049-6055.
4. Fridovich, I. Superoxide dismutases. An adaptation to aparamagnetic gas. J. Biol. Chem., 1989, 264(14), 7761-7764.
5. Johnson, F.; Giulivi, C. Superoxide dismutases and their impactupon human health. Mol. Aspects Med., 2005, 26(4-5), 340-352.
6. Finkel, T. Radical medicine: treating ageing to cure disease. Nat.Rev. Mol. Cell. Biol., 2005, 6(12), 971-976.
7. Wang, Z.Q.; Porreca, F.; Cuzzocrea, S.; Galen, K.; Lightfoot, R.; Masini, E.; Muscoli, C.; Mollace, V.; Ndengele, M.; Ischiropoulos, H.; Salvemini, D. A newly identified role for superoxide ininflammatory pain. J. Pharmacol. Exp. Ther., 2004, 309(3), 869-878.
8. Reddy, J.K.; Rao, M.S. Oxidative DNA damage caused bypersistent peroxisome proliferation: its role in hepatocarcino-genesis. Mutat. Res., 1989, 214(1), 63-68.
9. Dickinson, D.A.; Forman, H.J. Glutathione in defense andsignaling: lessons from a small thiol. Ann. N.Y. Acad. Sci., 2002,973, 488-504.
10. Mittal, C.K.; Murad, F. Activation of guanylate cyclase bysuperoxide dismutase and hydroxyl radical: a physiologicalregulator of guanosine 3',5'-monophosphate formation. Proc. Natl.Acad. Sci. USA, 1977, 74(10), 4360-4364.
11. Salvemini, D.; Riley, D.P. Nonpeptidyl mimetics of superoxidedismutase in clinical therapies for diseases. Cell. Mol. Life Sci.,2000, 57(11), 1489-1492.
12. Ignarro, L.J.; Buga, G.M.; Wood, K.S.; Byrns R.E.; Chaudhuri, G. Endothelium-derived relaxing factor produced and released fromartery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA, 1987,84(24), 9265-9269.
13. Palmer, R.M.; Ferrige, A.G.; Moncada, S. Nitric oxide releaseaccounts for the biological activity of endothelium-derived relaxingfactor. Nature, 1987, 327(6122), 524-526.
14. Moncada, S.; Higgs, E.A. Molecular mechanisms and therapeuticstrategies related to nitric oxide. FASEB J., 1995, 9(13), 1319-1330.
15. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J., 1992, 6, 3051-64.
16. Thiemermann, C. The role of the L-arginine: nitric oxide pathwayin circulatory shock. Adv. Pharmacol., 1994, 28, 45-79.tyrosine by peroxynitrite. Evidence for hydroxyl radical productionfrom peroxynitrite. FEBS Lett., 1994, 339(1-2), 89-92.
17. Radi, R.; Beckman, J.S.; Bush, K.M.; Freeman, B.A. Peroxynitriteinduced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys., 1991, 288(2), 481-487.
18. Radi, R.; Beckman, J.S.; Bush, K.M.; Freeman, B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 1991, 266(7), 4244-4250
19. van der Vliet, A.; O'Neill, C.A.; Halliwell, B.; Cross, C.E.; Kaur, H. Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. Evidence for hydroxyl radical production from peroxynitrite. FEBS Lett., 1994, 339(1-2), 89-92.
20. Ferrer-Sueta, G.; Radi, R. Chemical biology of peroxynitrite:kinetics, diffusion, and radicals. ACS Chem. Biol., 2009, 4(3), 161-177.
21. Muscoli, C.; Cuzzocrea, S.; Riley, D.P.; Zweier, J.L.; Thiemermann, C.; Wang, Z.Q.; Salvemini, D. On the selectivity of superoxidedismutase mimetics and its importance in pharmacological studies.Br. J. Pharmacol., 2003, 140(3), 445-460.
22. Petkau, A. Scientific basis for the clinical use of superoxidedismutase. Cancer Treat. Rev., 1986, 13(1), 17-44.
23. McCord, J.M.; Edeas, M.A. SOD, oxidative stress and humanpathologies: a brief history and a future vision. Biomed.Pharmacother., 2005, 59(5), 139-142.
24. Slemmer, J.E.; Shacka, J.J.; Sweeney, M.I.; Weber, J.T. Antioxidants and free radical scavengers for the treatment ofstroke, traumatic brain injury and aging. Curr. Med. Chem., 2008,15(4), 404-414.
25. Riley, D.P.; Weiss, R.H. Manganese macrocyclic ligand complexesas mimics of superoxide dismutase. J. Am. Chem. Soc., 1994,116(1), 387-388.
26. Baker, K.; Bucay Marcus, C.; Kruk, H.; Malfroy, B.; Doctrow, S.R. Synthetic combined superoxide dismutase/catalase mimetics areprotective as a delayed treatment in a rat stoke model: a key rolefor a reactive oxygen species in ischemic brain injury. J.Pharmacol. Exp. Ther., 1998, 284(1), 215-221.
27. Salvemini, D.; Riley, D.P.; Cuzzocrea, S. SOD mimetics arecoming of age. Nature Rev. Drug Discov., 2002, 1(5), 367-374.
28. Sheng, H.; Enghild, J.J.; Bowler, R.; Pate, M.; Batinic-Habererle, I.; Calvi, C.L.; Day, B.J.; Pearlstein, R.D.; Crapo, J.D.; Warner, D.S. Effect of metalloporphyrin catalytic antioxidants in experimentalbrain ischemia. Free Radic. Biol. Med., 2002, 33(7), 947-961.
29. Fricker, S.P. Nitric oxide scavengers as a therapeutic approach tonitric oxide mediated disease. Expert Opin. Investig. Drugs., 1999,8(8), 1209-1222.
30. Fricker, S.P. Metal complexes as therapeutic agents in nitrogenmonoxide modulation. In: Metal Ions in Biological Systems; Vol 41. Sigel, A.; Sigel, H. Eds.; Marcel Dekker: NY, 2004; pp. 421-480.
31. Cotton, F.A.; Wilkinson, G. Advanced Inorganic Chemistry. JohnWiley & Sons: NY, 1998.
32. Enemark, J.H.; Feltham, R.D. Principles of structure, bonding, andreactivity for metal nitrosyl complexes Coord. Chem.Rev., 1974, 13(4), 339-406.
33. Salerno, L.; Sorrenti, V.; Di Giacomo, C.; Romeo, G.; Siracusa,M.A. Progress in the development of selective nitric oxide synthase(NOS) inhibitors. Curr. Pharm. Des., 2002, 8(3), 177-200.
34. Yates, D.H.; Kharitonov, S.A.; Thomas, P.S.; Barnes, P.J.Endogenous nitric oxide is decreased in asthmatic patients by aninhibitor of inducible nitric oxide synthase. Am. J. Respir. Crit.Care Med., 1996, 154(1), 247-250.
35. Cobb, J.P. Nitric oxide synthase inhibition as therapy for sepsis: adecade of promise. Surg. Infect. (Larchmt), 2001, 2(2), 93-100.
36. Hansel, T.T.; Kharitonov, S.A.; Donnelly, L.E.; Erin, E.M.; Currie, M.G.; Moore, W.M.; Manning, P.T.; Recker, D.P.; Barnes, P.J. Aselective inhibitor of inducible nitric oxide synthase inhibitsexhaled breath nitric oxide in healthy volunteers and asthmatics.FASEB J., 2003, 17(10), 1298-1300.
37. Flitney, F.W.; Megson, I.L.; Flitney, D.E.; Butler, A.R. Iron-sulphur cluster nitrosyls, a novel class of nitric oxide generator:mechanism of vasodilator action on rat isolated tail artery. Br. J.Pharmacol., 1992, 107(3), 842-848.
38. Kilbourn, R.G.; Joly, G.; Cashon, B.; DeAngelo, J.; Bonaventura, J.Cell-free hemoglobin reverses the endotoxin-mediatedhyporesponsivity of rat aortic rings to alpha-adrenergic agents.Biochem. Biophys. Res. Commun., 1994, 199(1), 155-162.
39. Sharma, A.C.; Gulati, A. Effect of diaspirin cross-linkedhemoglobin and norepinephrine on systemic hemodynamics and.regional circulation in rats. J. Lab. Clin. Med., 1994, 123(2), 299-308.
40. Heneka, M.T.; Löschmann, P.A.; Osswald, H. Polymerizedhemoglobin restores cardiovascular and kidney function inendotoxin-induced shock in the rat. J. Clin. Invest., 1997, 99(1),47-54.
41. Bone, H.G.; Fischer, S.R.; Schenarts, P.J.; McGuire, R.; Traber, L.D.; Traber, D.L. Continuous infusion of pyridoxalatedhemoglobin polyoxyethylene conjugate in hyperdynamic septicsheep. Shock, 1998, 10(1), 69-76.
42. Reah, G.; Bodenham, A.R.; Mallick, A.; Daily, E.K.; Przybelski, R.J. Initial evaluation of diaspirin cross-linked hemoglobin(DCLHb) as a vasopressor in critically ill patients. Crit. Care Med.,1997, 25(9), 1480-1488.
43. De Angelo, J. Nitric oxide scavengers in the treatment of shockassociated with systemic inflammatory response syndrome. Exp.Opin. Pharmacother., 1999, 1(1), 19-29.
44. Cameron, B.R.; Darkes, M.C.; Yee, H.; Olsen, M.; Fricker, S.P.; Skerlj, R.T.; Bridger, G.J.; Davies, N.A.; Wilson, M.T.; Rose, D.J.; Zubieta, J. Ruthenium(III) polyaminocarboxylate complexes:efficient and effective nitric oxide scavengers. Inorg. Chem., 2003,42(6), 1868-1876.
45. Rajanayagam, M.A.; Li, C.G.; Rand, M.J. Differential effectsof hydroxocobalamin on NO-mediated relaxations in rat aortaand anococcygeus muscle. Br. J. Pharmacol., 1993, 108(1), 3-5.
46. Greenberg, S.S.; Xie, J.; Zatarain, J.M.; Kapusta, D.R.; Miller, M.J.Hydroxocobalamin (vitamin B12a) prevents and reversesendotoxin-induced hypotension and mortality in rodents: role ofnitric oxide. J. Pharmacol. Exp. Ther., 1995, 273(1), 257-265.
47. Rochelle, L.G.; Morana, S.J.; Kruszyna, H.; Russell, M.A.; Wilcox, D.E.; Smith, R.P. Interactions between hydroxocobalamin andnitric oxide (NO): evidence for a redox reaction between NO andreduced cobalamin and reversible NO binding to oxidizedcobalamin J. Pharmacol. Exp. Ther., 1995, 275(1), 48-52.
48. Firth, R.A.; Hill, H.A.O.; Pratt, J.M.; Thorp, R.G.; Williams, R.J.P. Chemistry of vitamin B12. Part XI. Some further formationconstants. J. Chem. Soc. A, 1969, (2), 381-386.
49. Wolak, M.; Stockel, G.; Hanza, M.; Van Eldik, R. Aquacobalamin(vitamin B12a) does not bind NO in aqueous solution. Nitriteimpurities account for observed reaction. Inorg. Chem., 2000,39(10), 2018-2019.
50. Wolak, M.; Zahl, A.; Schneppensieper, T.; Stockel, G.; Van Eldik,R. Kinetics and mechanism of the reversible binding of nitric oxideto reduced cobalaminn B12r (cob(II)alamin). J. Am. Chem. Soc.,2001, 123(40), 9780-9791.
51. Selçuki, C.; van Eldic, R.; Clark, T. NO binding to cobalamin:influence of the metal oxidation state. Inorg. Chem., 2004, 43(9),2828-2833.
52. Franke, A.; Roncaroli, F.; van Eldik, R. Mechanistic study on theactivation of NO by iron and cobalt complexes. Eur. J. Inorg.Chem., 2007, 2007(6), 773-798.
53. Sharma, V.S.; Pilz, R.B.; Boss, G.R.; Magde, D. Reactions of nitricoxide with vitamin B12 and its precursor, cobinamide. Biochemistry, 2003, 42(29), 8900-8908.
54. van der Kuy, P.H.; Merkus, F.W.; Lohman, J.J.; ter Berg, J.W.;Hooymans, P.M. Hydroxocobalamin, a nitric oxide scavenger, inthe prophylaxis of migraine: an open, pilot study. Cephalalgia,2002, 22(9), 513-517.
55. Kazmierski, W.M.; Wolberg, G.; Wilson, J.G.; Smith, S.R.; Williams, D.S.; Thorp, H.H.; Molina, L. Iron chelates bind nitricoxide and decrease mortality in an experimental model of septicshock. Proc. Natl. Acad. Sci. USA, 1996, 93(17), 9138-9141.
56. Molina, L.; Studenberg, S.; Wolberg, G.; Kazmierski, W.; Wilson, J.; Tadepalli, A.; Chang, A.C.; Kosanke, S.; Hinshaw, L. Efficacyof treatment with the iron (III) complex of diethylenetriaminepentaacetic acid in mice and primates inoculated with livelethal dose 100 Escherichia coli. J. Clin. Invest., 1996, 98(1), 192-198.
57. Zang, V.; Kotowski, M.; van Eldin, R. Kinetic and mechanism ofthe formation of FeII(EDTA)NO in the system FeII(EDTA)/NO/HONO/NO2-. Inorg. Chem., 1988, 27(9), 3279-3283.
58. Schneppensieper, T.; Finkler, S.; Czap, A.; van Eldik, R.; Heus, M.; Nieuwenhuizen, P.; Wreesmann, C.; Abma, W. Tuning thereversible binding of NO to iron(II) aminocarboxylate and relatedcomplexes in aqueous solution. Eur. J. Inorg.Chem., 2001, 2001(2), 491-501.
59. Schneppensieper, T.; Wanat, A.; Stochel, G.; Goldstein, S.; Meyerstein D.; van Eldik, R. Ligand effect on the kinetic of thereversible bindin of NO to selected aminocarboxylato complexes ofiron(II) in aqueous solution. Eur. J. Inorg. Chem., 2001, 9, 2317-2325.
60. Wolak, M.; van Eldik, R. To be or not to be in coordinationchemistry? A mechanistic approach. Coord. Chem. Rev., 2002,230(1-2), 263-282.
61. Schneppensieper, T.; Wanat, A.; Stochel, G.; van Eldik, R.; Mechanistic information on the reversible binding of NO toselected iron(II) chelates from activation parameters. Inorg. Chem.,2002, 41(9), 2565-2573.
62. Mizuta, T.; Wang, J.; Miyoshi, K.; Molecular structures of Fe(II)complexes with mono- and diprotonated ethylenediamine-N,N,N',N'-tetraacetate (Hedta and H2edta), as determined by X-raycrystal analyses. Inorg. Chim. Acta, 1995, 230(1-2), 119-125.
63. Yoshimura, T.; Kotake, Y. Spin trapping of nitric oxide with theiron-dithiocarbamate complex: chemistry and biology. Antioxid.Redox. Sign., 2004, 6(3), 639-647.
64. Nadler, E.P.; Dickinson, E.C.; Beer-Stolz, D.; Alber, S.M.; Watkins, S.C.; Pratt, D.W.; Ford, H.R. Scavenging nitric oxidereduces hepatocellular injury after endotoxin challenge. Am. J.Physiol. Gastrointest. Liver Physiol., 2001, 281(1), G173-G181.
65. Roza, A.M.; Cooper, M.; Pieper, G.; Hilton, G.; Dembny, K.; Lai, C.S.; Lindholm, P.; Komorowski, R.; Felix, C.; Johnson, C.; Adams, M. NOX 100, a nitric oxide scavenger, enhances cardiacallograft survival and promotes long-term graft acceptance. Transplantation, 2000, 69(2), 227-231.
66. Pieper, G.M.; Dembny, K.; Siebeneich, W. Long-term treatment invivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction. Diabetologia, 1998, 41(10), 1220-1226.
67. Bottomley, F. Nitrosyl complexes of ruthenium. Coord. Chem.Rev., 1978, 26(1), 7-32.
68. Marmion, C.J.; Cameron, B.; Mulcahy, C.; Fricker, S.P. Rutheniumas an effective nitric oxide scavenger. Curr. Top. Med. Chem.,2004, 4(15), 1585-1603.
69. Storr, T.; Cameron, B.R.; Gossage, R.A.; Yee, H.; Skerlj, R.T.; Darkes, M.C.; Fricker, S.P.; Bridger, G.J.; Davies, N.A.; Wilson, M.T.; Maresca, K.P.; Zubieta, J. Ru III complexes of EDTA and DTPA polyaminocarboxylate analogues and their use as nitricoxide scavengers. Eur. J. Inorg. Chem., 2005, 2685-2697.
70. Bajaj, H.C.; van Eldik, R. Kinetics and mechanism of the ligandsubstitution reactions of ethylenediaminetetraacetate complexes ofruthenium(III) in aqueous solution. Inorg. Chem., 1988, 27(22),4052-4055.
71. Bajaj, H.C.; van Eldik, R. Influence of the pendant group on thesubstitution lability of N-substituted ethylenediaminetriacetatecomplexes of ruthenium(III) in aqueous solution. Inorg. Chem.,1990, 29(15), 2855-2858.
72. Ford, P.C.; Lavermann, L.E. Reaction mechanism relevant to theformation of iron and ruthenium nitric oxide complexes. Coord.Chem. Rev., 2005, 249(3-4), 391-403.
73. Baggs, G.; Fricker, S.P.; Abrams, M.; Lee, C.; Fink, M.P. A novelruthenium-based nitric oxide scavenger ameliorates acute lunginjury in porcine endotoxemia. Surg. Forum., 1997, 48(1), 84-86.
74. Fricker, S.P.; Slade, E.; Powell, N.A.; Vaughan, O.J.; Henderson, G.R.; Murrer, B.A.; Megson, I.L.; Bisland, S.K.; Flitney, F.W. Ruthenium complexes as nitric oxide scavengers: a potentialtherapeutic approach to nitric oxide-mediated diseases. Br. J.Pharmacol., 1997, 122(7), 1441-1449.
75. Bambagioni, V.; Bani, D.; Bencini, A.; Biver, T.; Cantore, M.; Chelli, R.; Cinci, L.; Failli, P.; Grezzi, L.; Giorni, C.; Nappini, S.; Secco, F.; Tinè, M.R.; Valtancoli, B.; Venturini, M. Polyamine-polycarboxylate metal complexes with different biologicaleffectiveness as nitric oxide scavengers. Clues for drug design. J.Med. Chem., 2008, 51(11), 3250-3260.
76. 2O. Acta Cryst., 1988, C44, 981-986.
77. Komarov, A.M.; Lai, C.S. Detection of nitric oxide production inmice by spin-trapping electron paramagnetic resonancespectroscopy. Biochim. Biophys. Acta, 1995, 1272(1), 29-36.
78. 2+ with diethyldithiocarbamate or N-methyl-D-glucamine dithiocarbamate as traps of nitric oxide inanimal tissues: comparative investigations. Biochim. Biophis Acta,1997, 1336(3), 225-234.
79. Harbrecht, B.G. Therapeutic use of nitric oxide scavengers in shockand sepsis. Curr. Pharm. Des., 2006, 12(27), 3543-3549.
80. Riley, D.P. Functional mimics of superoxide dismutase enzymes astherapeutic agents. Chem. Rev., 1999, 99(9), 2573-2588.
81. Zhang, C.X.; Lippard, S.J. New metal complexes as potentialtherapeutics. Curr. Opin. Chem. Biol., 2003, 7(4), 481-489.
82. Cuzzocrea, S; Thiemermann, C.; Salvemini, D. Potentialtherapeutic effect of antioxidant therapy in shock andinflammation. Curr. Med. Chem., 2004, 11(9), 1147-1162.
83. Wu, A.J.; Penner-Hahn, J.E.; Pecoraro, V.L. Structural,spectroscopic, and reactivity models for the manganese catalases.Chem. Rev., 2004, 104(2), 903-938.
84. Riley, D.P.; Schall, O.F. Structure-activity studies and the designof synthetic superoxide dismutase (SOD) mimetics as therapeutics. Adv. Inorg. Chem., 2006, 59(1), 233-263.
85. Batinic-Haberle, I.; Reboucas, J.S.; Spasojevich, I. Superoxidedismutase mimics: chemistry, pharmacology and therapeuticpotential. Antioxid. Redox. Signal, 2010, Jan, 22. [Epub ahead ofprint].
86. Riley, D.P.; Lennon, P.J.; Neumann, W.L.; Weiss, R.H. Toward therational design of superoxide dismutase mimics: mechanisticstudies for the elucidation of substituent effects on the catalyticactivity of macrocyclic manganese(II) complexes. J. Am. Chem.Soc., 1997, 119(28), 6522-6528.
87. Salvemini, D.; Wang, Z.Q.; Zweier, J.L.; Samouilov, A; Macarthur, H.; Misko, T.P.; Currie, M.G.; Cuzzocrea, S.; Sikorski, J.A.; Riley, D.P. A nonpeptidyl mimic of superoxide dismutase withtherapeutic activity in rats. Science, 1999, 286(5438), 304-306.
88. Riley, D.P. Rational design of synthetic enzymes and their potentialutility as human pharmaceuticals: development of manganese(II)-based superoxide dismutase mimics. Adv. Supramol. Chem., 2000,6(1), 217-242.
89. Aston, K.V.; Rath, N.; Naik, A.; Slomczynska, U.; Schall, O.F.; Riley, D.P. Computer-aided design (CAD) of Mn(II) complexes:superoxide dismutase mimetics with catalytic activity exceedingthe native enzyme. Inorg. Chem., 2001, 40(8), 1779-1789.
90. Dees, A.; Zahl, A.; Puchta, R.; van Eikema Hommes, N.J.R.; Heinemann, F.W.; Ivanovi-Burmazovi, I. Water exchange onseven-coordinate Mn(II) complexes with macrocyclic pentadentateligands: insight in the mechanism of Mn(II) SOD mimetics. Inorg.Chem., 2007, 46(7), 2459-2470.
91. Ivanovi-Burmazovi, I. Catalytic dismutation vs. reversiblebinding of superoxide. Adv. Inorg. Chem., 2008, 60(1), 59-100.
92. Cuzzocrea, S.; Riley, D.P.; Caputi, A.P.; Salvemini, D. Antioxidanttherapy: a new pharmacological approach in shock, inflammation,and ischemia/reperfusion injury. Pharmacol. Rev., 2001, 53(1),135-159.
93. Salvemini, D.; Muscoli, C.; Riley, D.P.; Cuzzocrea, S. Superoxidedismutase mimetics. Superoxide, superoxide dismutase andischemic injury. Pulm. Pharmacol. Ther. 2002, 15, 439.
94. Salvemini, D., Cuzzocrea, S. Superoxide, superoxide dismutaseand ischemic injury. Curr. Opin. Investig. Drugs, 2002, 3(6), 886-895.
95. Masini, E.; Cuzzocrea, S.; Mazzon, E.; Marzocca, C.; Mannaioni, P.F.; Salvemini, D. Protective effects of M40403, a selectivesuperoxide dismutase mimetic, in myocardial ischaemia andreperfusion injury in vivo. Br. J. Pharmacol., 2002, 136(6), 905-917.
96. Xu, Y.; Liu, B.; Zweier, J.L.; He, G. Formation of hydrogenperoxide and reduction of peroxynitrite via dismutation ofsuperoxide at reperfusion enhances myocardial blood flow andoxygen consumption in postischemic mouse heart. J. Pharmacol.Exp. Ther., 2008, 327(2), 402-410.
97. Coppey, L.J.; Gellett, J.S.; Davidson, E.P.; Dunlap, J.A.; Lund, D.D.; Salvemini, D.; Yorek, M.A. Effect of M40403 treatment ofdiabetic rats on endoneurial blood flow, motor nerve conductionvelocity and vascular function of epineurial arterioles of the sciaticnerve. Br. J. Pharmacol., 2001, 134(1), 21-29.
98. Masini, E.; Bani, D.; Vannacci, A.; Pierpaoli, S.; Mannaioni, P.F.; Comhair, S.A.; Xu, W.; Muscoli, C.; Erzurum, S.C.; Salvemini, D. Reduction of antigen-induced respiratory abnormalities and airwayinflammation in sensitized guinea pigs by a superoxide dismutasemimetic. Free Radic. Biol. Med., 2005, 39(4), 520-531.
99. Cuzzocrea, S.; Mazzon, E.; Dugo, L.; Caputi, A.P.; Riley, D.P.; Salvemini, D. Protective effects of M40403, a superoxidedismutase mimetic, in a rodent model of colitis. Eur. J.Pharmacol., 2001, 432(1), 79-89.
100. Murphy, C.K.; Fey, E.G.; Watkins, B.A.; Wong, V.; Rothstein, D.; Sonis, S.T. Efficacy of superoxide dismutase mimetic M40403 inattenuating radiation-induced oral mucositis in hamsters. Clin.Cancer Res., 2008, 14(13), 4292-4297.
101. Salvemini, D.; Mazzon, E.; Dugo, L.; Serraino, I.; De Sarro, A.; Caputi, A.P.; Cuzzocrea, S. Amelioration of joint disease in a ratmodel of collagen-induced arthritis by M40403, a superoxidedismutase mimetic. Arthritis Rheum., 2001, 44(12), 2909-2921.
102. Shimizu, K.; Rajapakse, N.; Horiguchi, T.; Payne, R.M.; Busija,D.W. Neuroprotection against hypoxia-ischemia in neonatal ratbrain by novel superoxide dismutase mimetics. Neurosci. Lett.,2003, 346(1-2), 41-44.
103. Wang, C.; McInnis, J.; West, J.B.; Bao, J.; Anastasio, N.; Guidry, J.A.; Ye, Y.; Salvemini, D; Johnson, K.M. Blockade ofphencyclidine-induced cortical apoptosis and deficits in prepulseinhibition by M40403, a superoxide dismutase mimetic. J.Pharmacol. Exp. Ther., 2003, 304(1), 266-271.
104. Samlowski, W.E.; Petersen, R.; Cuzzocrea, S.; Macarthur, H.; Burton, D.; McGregor, J.R.; Salvemini, D. A nonpeptidyl mimic ofsuperoxide dismutase, M40403, inhibits dose-limiting hypotensionassociated with interleukin-2 and increases its antitumor effects. Nat. Med., 2003, 9(6), 750-755.
105. Cuzzocrea, S.; Mazzon, E.; di Paola, R.; Genovese, T.; Muià, C.; Caputi, A.P.; Salvemini, D. Synergistic interaction betweenmethotrexate and a superoxide dismutase mimetic: pharmacologicand potential clinical significance. Arthritis Rheum., 2005, 52(12),3755-3760.
106. Schmidt, C.K.; Brauch, H.J. Impact of aminopolycarboxylates onaquatic organisms and eutrophication: overview of available data. Environ. Toxicol., 2004, 19(6), 620-637.
107. Bencini, A.; Bianchi, A.; Micheloni, M.; Paoletti, P.; Garcia-España, E.; Niño, M.A. Co-ordination tendency of [3k]aneNkpolyazacycloalkanes. Thermodynamic study of solution equilibria. J. Chem. Soc. Dalton Trans., 1991, 5(1), 1171-1174.
108. Meyerstein, D. Are M-N bonds indeed inherently weaker when n isa tertiary rather than a primary or secondary nitrogen atom? Coord.Chem. Rev., 1999, 185-186, 141-147.
109. Failli, P.; Bani, D.; Bencini, A.; Cantore, M.; Di Cesare Mannelli, L.; Ghelardini, C.; Giorgi, C.; Innocenti, M.; Rugi, F.; Spepi, A.; Udisti, R.; Valtancoli, B. A novel manganese complex effective assuperoxide anion scavenger and therapeutic agent against cell andtissue oxidative injury. J. Med. Chem., 2009, 52(22), 7273-7283.
110. Cinci, L.; Masini, E.; Bencini, A.; Valtancoli, B.; Mastroianni, R.; Calosi, L.; Bani, D. Suppression of allergen-induced respiratorydysfunction and airway inflammation in sensitised guinea pigs byMnII(Me2DO2A), a novel superoxide scavenger compound. FreeRadic. Biol. Med., 2010, 48(11), 1525-1534.
111. Doctrow, S.R.; Huffman, K.; Marcus, C.B.; Tosco, G.; Malfroy, E.; Adinolfi, C.A.; Kruk, H.; Baker, K.; Lazarowych, N.; Mascarenhas, J.; Malfroy, B. Salen-manganese complexes as catalytic scavengersof hydrogen peroxide and cytoprotective agents: structure-activityrelationship studies. J. Med. Chem., 2002, 45(20), 4549-4558.
112. Doctrow, S.R.; Huffman, K.; Marcus, C.B.; Musleh, W.; Bruce, A.; Baudry, M.; Malfroy, B. Salen-manganese complexes: combinedsuperoxide dismutase/catalase mimics with broad pharmacologicalefficacy. Adv. Pharmacol., 1997, 38(1), 247-269.
113. Sharpe, M.A.; Ollosson, R.; Stewart, V.C.; Clark, J.B. Oxidation ofnitric oxide by oxomanganese-salen complexes: A new mechanismfor cellular protection by superoxide dismutase/catalase mimetics.Biochem. J., 2002, 366(Pt1), 97-107.
114. Liu, R.; Liu, I.Y.; Bi, X.; Thompson, R.F.; Doctrow, S.R.; Malfroy, B.; Baudry, M. Reversal of age-related learning deficits and brainoxidative stress in mice with superoxide dismutase/catalasemimetics. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8526-8531.
115. Brazier, M.W.; Doctrow, S.R.; Masters, C.L.; Collins, S.J. Amanganese-superoxide dismutase/catalase mimetic extends survivalin a mouse model of human prion disease. Free Radic. Biol. Med.,2008, 45(2), 184-192.
116. Melov, S.; Doctrow, S.R.; Schneider, J.A.; Haberson, J.; Patel, M.; Coskun, P.E.; Huffman, K.; Wallace, D.C.; Malfroy, B. Lifespanextension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci., 2001, 21(21), 8348-8353.
117. Srinivasan, V.; Doctrow, S.; Singh, V.K.; Whitnall, M.H.Evaluation of EUK-189, a synthetic superoxide dismutase/catalasemimetic as a radiation countermeasure. Immunopharmacol.Immunotoxicol., 2008, 30(2), 271-290.
118. Gonzalez, P.K.; Zhuang, J.; Doctrow, S.R.; Malfroy, B.; Benson, P.F.; Menconi, M.J.; Fink, M.P. Role of oxidant stress in the adultrespiratory distress syndrome: evaluation of a novel antioxidantstrategy in a porcine model of endotoxin-induced acute lung injury. Shock, 1996, 6 (Suppl 1), S23-S26.
119. van Empel, V.P.; Bertrand, A.T.; van Oort, R.J.; van der Nagel, R.; Engelen, M.; van Rijen, H.V.; Doevendans, P.A.; Crijns, H.J.; Ackerman, S.L.; Sluiter, W.; De Windt, L.J. EUK-8, a superoxidedismutase and catalase mimetic, reduces cardiac oxidative stressand ameliorates pressure overload-induced heart failure in theharlequin mouse mutant. J. Am. Coll. Cardiol., 2006, 48(4), 824-832.
120. Day, B.J. Antioxidants as potential therapeutics for lung fibrosis.Antiox. Redox Signal., 2008, 10(2), 355-370.
121. Williamson, M.M., Craig, L.H. Isolation and characterization of afive-coordinate manganese(III) porphyrin cation. Crystal andmolecular structure of aquo (etraphenylporphinato) manganese(III)triflate. Inorg. Chem., 1986, 25(26), 4668-4671.
122. Pasternack, R.F.; Skowronek, W.R. Catalysis of thedisproportionation of superoxide by metalloporphyrins. J. Inorg.Biochem., 1979, 11(3), 261-267.
123. Day, B.J.; Fridovich, I.; Crapo, J.D. Manganic porphyrins possesscatalase activity and protect endothelial cells against hydrogenperoxide-mediated injury. Arch. Biochem. Biophys., 1997, 347(2),256-262.
124. Szabo, C.; Day, B.J.; Salzman, A.L. Evaluation of the relativecontribution of nitric oxide and peroxynitrite to the suppression ofmitochondrial respiration in immunostimulated macrophages usinga manganese mesoporphyrin superoxide dismutase mimetic andperoxynitrite scavenger. Fed. Eur. Biochem. Soc. Lett., 1996,381(1-2), 82-86.
125. Day, B.J.; Batini-Haberle, I.; Crapo, J.D. Metalloporphyrins arepotent inhibitors of lipid peroxidation. Free Radic. Biol. Med.,1999, 26(5-6), 730-736.
126. Day, B.J. Catalase and glutathione peroxidase mimics. Biochem.Pharmacol., 2009, 77(3), 285-296.
127. Lee, J.; Hunt, J.A.; Grooves, J.T. Mechanisms of iron porphyrinreactions with peroxynitrite. J. Am. Chem. Soc., 1998, 120(30),7493-7501.
128. Patel, M.; Day, B.J. Metalloporphyrin class of therapeutic catalyticantioxidant. Trends Pharm. Sci., 1999, 20(9), 359-364.
129. Castello, P.R.; Drechsel, D.A.; Day, B.J.; Patel, M. Inhibition ofmitochondrial hydrogen peroxide production by lipophilicmetalloporphyrins. J. Pharmacol. Exp. Ther., 2008, 324(3), 970-976.
130. Kachadourian, R.; Johnson, C.A.; Min, E.; Spasojevic, I.; Day, B.J. Flavin-dependent antioxidant properties of a new series of meso-N, N -dialkyl-imidazolium substituted manganese(III) porphyrins.Biochem. Pharmacol., 2004, 67(1), 77-85.
131. Batini-Haberle, I; Spasojevi, I.; Hambright P.; Benov, L.; Crumbliss, A.L.; Fridovich, I. Relationship between redoxpotential, proton dissocation contsnts of pyrrolic nitrogens, and invivo and in vitro superoxide dismutating activies of manganese(III)and iron(III) water-soluble porphyrins. Inorg. Chem., 1999, 38(18),4011-4022.
132. Batini-Haberle, I.; Cuzzocrea, S.; Rebouças, J.S.; Ferrer-Sueta, G.; Mazzon, E.; Di Paola, R.; Radi, R.; Spasojevi, I; Benov, L.; Salvemini, D. Pure MnTBAP selectively scavenges peroxynitriteover superoxide: Comparison of pure and commercial MnTBAPsamples to MnTE-2-PyP in two models of oxidative stress injury,an SOD-specific Escherichia coli model and carrageenan-inducedpleurisy. Free Radic. Biol. Med., 2009, 46(2), 192-201.
133. Day, B.J. Catalytic antioxidants: a radical approach to newtherapeutics. Drug Discov. Today, 2004, 9(13), 557-566.
134. Kontos, H.A.; Povlishock, J.T. Oxygen radicals in brain injury. Cent. Nerv. Syst. Trauma, 1986, 3(4), 257-263.
135. Yang, G.; Chan, P.H.; Chen, J.; Carlson, E.; Chen, S.F.; Weinstein, P.; Epstein, C.J.; Kamii, H. Human copper-zinc superoxidedismutase transgenic mice are highly resistant to reperfusion injuryafter focal cerebral ischemia. Stroke, 1994, 25(1), 165-170.
136. Kondo, T.; Reaume, A.G.; Huang, T.T.; Carlson, E.; Murakami, K.; Chen, S.F.; Hoffman, E.K.; Scott, R.W.; Epstein, C.J.; Chan, P.H. Reduction of CuZn-superoxide dismutase activity exacerbatesneuronal cell injury and edema formation after transient focalcerebral ischemia. J. Neurosci., 1997, 17(11), 4180-4189.
137. Batini -Haberle, I.; Benov, L.; Spasojevic, I.; Fridovich, I. Theortho effect makes manganese(III) meso-tetrakis (N-methylpyridinium-2-yl)porphyrin (MnTM-2-Pyp5+) a powerful andpotentially useful superoxide dismutase mimic. J. Biol. Chem.,1998, 273(38), 24521-24528.
138. Mackensen, G.B.; Patel, M.; Sheng, H.; Calvi, C.; Batini-Haberle, I.; Day, B.J.; Liang, L.P.; Fridovich, I.; Crapo, J.D.; Pearlstein, R.D.; Warner, D.S. Neuroprotection from delayed post-ischemicadministration of a metalloporphyrin catalytic antioxidant. J.Neurosci., 2001, 21(13), 4582-4592.
139. Oury, T.D.; Thakker, K.; Menache, M.; Chang, L.Y.; Crapo, J.D.; Day, B.J. Attenuation of bleomycin-induced pulmonary fibrosis bya catalytic antioxidant metalloporphyrin. Am. J. Respir. Cell. Mol.Biol., 2001, 25(2), 164-169.
140. Vujaskovic, Z.; Batini-Haberle, I.; Rabbani, Z.N.; Feng, Q.F.; Kang, S.K.; Spasojevic, I.; Samulski, T.V.; Fridovich, I.; Dewhirst, M.W.; Anscher, M.S. A small molecular weight catalyticmetalloporphyrin antioxidant with superoxide dismutase (SOD)mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med., 2002, 33(6), 857-863.
141. Liang, L.P.; Huang, J.; Fulton, R.; Day, B.J.; Patel, M. An orallyactive catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J.Neurosci., 2007, 27(16), 4326-4333.
142. Rosenthal, R.A.; Huffman, K.D.; Fisette, L.W.; Damphousse, C.A.; Callaway, W.B.; Malfroy, B.; Doctrow, S.R. Orally available Mnporphyrins with superoxide dismutase and catalase activities. J.Biol. Inorg. Chem., 2009, 14(6), 979-991.